SG11201907050PA - Method for treating egfr-tki-resistant non-small cell lung cancer by administration of anti-her3 antibody-drug conjugate - Google Patents
Method for treating egfr-tki-resistant non-small cell lung cancer by administration of anti-her3 antibody-drug conjugateInfo
- Publication number
- SG11201907050PA SG11201907050PA SG11201907050PA SG11201907050PA SG11201907050PA SG 11201907050P A SG11201907050P A SG 11201907050PA SG 11201907050P A SG11201907050P A SG 11201907050PA SG 11201907050P A SG11201907050P A SG 11201907050PA SG 11201907050P A SG11201907050P A SG 11201907050PA
- Authority
- SG
- Singapore
- Prior art keywords
- tki
- administration
- lung cancer
- small cell
- cell lung
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title 1
- 229940049595 antibody-drug conjugate Drugs 0.000 title 1
- 229940121647 egfr inhibitor Drugs 0.000 title 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 title 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/86—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017035919 | 2017-02-28 | ||
JP2017199883 | 2017-10-13 | ||
PCT/JP2018/007152 WO2018159582A1 (ja) | 2017-02-28 | 2018-02-27 | 抗her3抗体-薬物コンジュゲート投与によるegfr-tki抵抗性の非小細胞肺癌の治療方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201907050PA true SG11201907050PA (en) | 2019-09-27 |
Family
ID=63369984
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201907050PA SG11201907050PA (en) | 2017-02-28 | 2018-02-27 | Method for treating egfr-tki-resistant non-small cell lung cancer by administration of anti-her3 antibody-drug conjugate |
Country Status (11)
Country | Link |
---|---|
US (1) | US20200061031A1 (de) |
EP (1) | EP3590534A4 (de) |
JP (2) | JP7181181B2 (de) |
KR (2) | KR20190120764A (de) |
CN (2) | CN110475569B (de) |
AU (1) | AU2018227146A1 (de) |
BR (1) | BR112019015915A2 (de) |
CA (1) | CA3053749A1 (de) |
SG (1) | SG11201907050PA (de) |
TW (1) | TW201834696A (de) |
WO (1) | WO2018159582A1 (de) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210062005A (ko) * | 2018-09-20 | 2021-05-28 | 다이이찌 산쿄 가부시키가이샤 | 항 her3 항체-약물 콘쥬게이트 투여에 의한 her3 변이암의 치료 |
US20220040324A1 (en) * | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
PT3946464T (pt) | 2019-03-29 | 2022-11-16 | Medimmune Ltd | Compostos e seus conjugados |
US20240026028A1 (en) * | 2020-10-14 | 2024-01-25 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-her3 antibody and anti-her3 antibody-drug conjugate and medical use thereof |
WO2022116141A1 (zh) * | 2020-12-04 | 2022-06-09 | 上海复旦张江生物医药股份有限公司 | 抗体药物偶联物、其中间体、制备方法及应用 |
AU2022293634A1 (en) * | 2021-06-15 | 2024-01-18 | Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd. | Anti-her3 antibody, antibody drug conjugate containing the same, and use thereof |
US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
WO2023143263A1 (zh) * | 2022-01-25 | 2023-08-03 | 苏州宜联生物医药有限公司 | 一种针对Her3的抗体,偶联物及其用途 |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
EP1400536A1 (de) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Verfahren zur Herstellung humanisierter Antikörper |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
CN102311986B (zh) | 2000-10-06 | 2015-08-19 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
US6774116B2 (en) | 2001-04-17 | 2004-08-10 | Cryolife, Inc. | Prodrugs via acylation with cinnamate |
WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
US7591994B2 (en) | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
EP1572242B1 (de) | 2002-12-13 | 2014-04-16 | Immunomedics, Inc. | Immun-conjugate mit einem intrazellular spaltbaren linker |
US7517903B2 (en) | 2004-05-19 | 2009-04-14 | Medarex, Inc. | Cytotoxic compounds and conjugates |
WO2006135371A1 (en) | 2005-06-09 | 2006-12-21 | Kosan Biosciences Incorporated | Conjugates with reduced adverse systemic effects |
AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
WO2008033891A2 (en) | 2006-09-12 | 2008-03-20 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Azonafide derived tumor and cancer targeting compounds |
CA2670315A1 (en) * | 2006-11-21 | 2008-11-20 | The Regents Of The University Of California | Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof |
EP3248617A3 (de) | 2007-02-16 | 2018-02-21 | Merrimack Pharmaceuticals, Inc. | Antikörper gegen erbb3 und verwendungen davon |
SI2281006T1 (sl) | 2008-04-30 | 2017-12-29 | Immunogen, Inc. | Premreževalci in njihova uporaba |
BRPI0911442A2 (pt) | 2008-04-30 | 2019-03-12 | Immunogen, Inc. | conjugados potentes e ligantes hidrofílicos |
CN102448494B (zh) | 2009-02-13 | 2016-02-03 | 免疫医疗公司 | 具有胞内可裂解的键的免疫共轭物 |
TWI461211B (zh) | 2009-03-20 | 2014-11-21 | Genentech Inc | 抗-her抗體 |
JP2013507926A (ja) | 2009-10-14 | 2013-03-07 | メリマック ファーマシューティカルズ インコーポレーティッド | IGF−1R及びErbB3シグナル伝達を標的とする二重特異的結合剤及びその使用 |
TWI630916B (zh) * | 2009-11-13 | 2018-08-01 | 第一三共歐洲公司 | 供治療或預防人表皮生長因子受體-3(her-3)相關疾病之藥料和方法 |
ES2566602T3 (es) | 2010-04-09 | 2016-04-14 | Aveo Pharmaceuticals, Inc. | Anticuerpos anti-ErbB3 |
AU2011239525B2 (en) | 2010-04-15 | 2015-04-09 | Medimmune Limited | Pyrrolobenzodiazepines used to treat proliferative diseases |
EA024118B1 (ru) | 2010-04-15 | 2016-08-31 | Сиэтл Дженетикс, Инк. | Конъюгаты пирролбензодиазепина направленного действия |
WO2012019024A2 (en) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Her3-binding molecules and immunoconjugates thereof |
PT2606070T (pt) | 2010-08-20 | 2017-03-31 | Novartis Ag | Anticorpos para o recetor 3 do fator de crescimento epidérmico (her3) |
US20130330350A1 (en) | 2010-11-09 | 2013-12-12 | Medimmune, Llc | Antibody Scaffold For Homogenous Conjugation |
EP2760893B1 (de) | 2011-09-30 | 2018-09-12 | Regeneron Pharmaceuticals, Inc. | Anti-erbb3-antikörper und verwendungen davon |
EP3309162A1 (de) | 2011-10-14 | 2018-04-18 | Seattle Genetics, Inc. | Gerichtete konjugate der pyrrolobenzodiazepine |
PT2773671T (pt) | 2011-11-04 | 2021-12-14 | Zymeworks Inc | Geração de anticorpo heterodimérico estável com mutações no domínio fc |
RU2620068C2 (ru) * | 2011-11-23 | 2017-05-22 | МЕДИММЬЮН, ЭлЭлСи | Связывающие молекулы, специфичные по отношению к her3, и их применения |
AU2013255537B2 (en) * | 2012-05-02 | 2018-02-15 | Symphogen A/S | Humanized pan-her antibody compositions |
KR102584005B1 (ko) | 2012-10-11 | 2023-09-27 | 다이이찌 산쿄 가부시키가이샤 | 글리신아미드 화합물의 제조 방법 |
JP6272230B2 (ja) | 2012-10-19 | 2018-01-31 | 第一三共株式会社 | 親水性構造を含むリンカーで結合させた抗体−薬物コンジュゲート |
JP6262768B2 (ja) | 2013-01-03 | 2018-01-17 | セルトリオン, インク. | 抗体−リンカー−薬物結合体、その製造方法およびそれを含む抗癌剤組成物 |
AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
WO2014134457A2 (en) | 2013-02-28 | 2014-09-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
JP6847388B2 (ja) | 2013-03-15 | 2021-03-31 | レゲネロン ファーマシューティカルス,インコーポレーテッド | 生物活性分子、そのコンジュゲート、及び治療用途 |
CN105829346B (zh) * | 2014-01-31 | 2019-08-23 | 第一三共株式会社 | 抗her2抗体-药物偶联物 |
ES2859648T3 (es) * | 2014-04-10 | 2021-10-04 | Daiichi Sankyo Co Ltd | Conjugado anticuerpo-fármaco anti-HER3 |
MX2016014862A (es) * | 2014-05-14 | 2017-02-27 | Hoffmann La Roche | Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2. |
CA2959716A1 (en) * | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Anti-her3 antibodies and uses of same |
CA2991799A1 (en) * | 2015-07-15 | 2017-01-19 | Zymeworks Inc. | Drug-conjugated bi-specific antigen-binding constructs |
-
2018
- 2018-02-27 TW TW107106568A patent/TW201834696A/zh unknown
- 2018-02-27 EP EP18760248.7A patent/EP3590534A4/de active Pending
- 2018-02-27 BR BR112019015915A patent/BR112019015915A2/pt unknown
- 2018-02-27 CA CA3053749A patent/CA3053749A1/en active Pending
- 2018-02-27 WO PCT/JP2018/007152 patent/WO2018159582A1/ja unknown
- 2018-02-27 CN CN201880014522.3A patent/CN110475569B/zh active Active
- 2018-02-27 AU AU2018227146A patent/AU2018227146A1/en active Pending
- 2018-02-27 SG SG11201907050PA patent/SG11201907050PA/en unknown
- 2018-02-27 JP JP2019503002A patent/JP7181181B2/ja active Active
- 2018-02-27 US US16/485,777 patent/US20200061031A1/en active Pending
- 2018-02-27 CN CN202311461736.4A patent/CN117982673A/zh active Pending
- 2018-02-27 KR KR1020197025656A patent/KR20190120764A/ko not_active Application Discontinuation
- 2018-02-27 KR KR1020247015733A patent/KR20240074000A/ko active Search and Examination
-
2022
- 2022-09-30 JP JP2022157622A patent/JP2022173482A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3053749A1 (en) | 2018-09-07 |
CN117982673A (zh) | 2024-05-07 |
CN110475569B (zh) | 2023-11-21 |
JP2022173482A (ja) | 2022-11-18 |
AU2018227146A1 (en) | 2019-08-29 |
JP7181181B2 (ja) | 2022-11-30 |
CN110475569A (zh) | 2019-11-19 |
EP3590534A4 (de) | 2020-12-23 |
JPWO2018159582A1 (ja) | 2019-12-19 |
US20200061031A1 (en) | 2020-02-27 |
EP3590534A1 (de) | 2020-01-08 |
KR20190120764A (ko) | 2019-10-24 |
BR112019015915A2 (pt) | 2020-04-07 |
KR20240074000A (ko) | 2024-05-27 |
WO2018159582A1 (ja) | 2018-09-07 |
TW201834696A (zh) | 2018-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201907050PA (en) | Method for treating egfr-tki-resistant non-small cell lung cancer by administration of anti-her3 antibody-drug conjugate | |
IL276481B (en) | Anti-b7-h1 and anti-ctla-4 antibodies for the treatment of non-small cell lung cancer | |
IL293177A (en) | Preparation method for drug conjugates - antibody against - her3 | |
SG11202000997YA (en) | Improved method for producing antibody-drug conjugate | |
IL272964A (en) | Production method for antibody-drug conjugates | |
PH12017502142A1 (en) | Tetrasubstituted aklene compounds and their use | |
IL259423A (en) | Combination therapy of tetracyclic quinolone analogs for the treatment of cancer | |
IL253979B (en) | Methods, preparations and kits for cancer treatment | |
IL259773A (en) | Mat2a inhibitors for treating mtap null cancer | |
HK1247578A1 (zh) | 用於治療非小細胞肺癌的組合抗pd-l1和抗ctla4抗體 | |
HK1252370A1 (zh) | 用於治療非小細胞肺癌的治療方法和組合物 | |
EP3684420A4 (de) | Verfahren zur behandlung von dreifach negativem brustkrebs | |
TW201613615A (en) | Antagonists for interleukin-17 receptor B (IL-17RB) and its ligand IL-17B for cancer therapy | |
IL268163A (en) | Methods, compositions, and kits for treatment of cancer | |
IL280830A (en) | Bracelets for use in cancer treatment methods | |
EP3289084A4 (de) | Sirna-hemmung der expression des menschlichen antigens r zur behandlung von krebs | |
MX2015013021A (es) | 5-bromo-indirrubinas. | |
EP3295949A4 (de) | Topisches arzneimittel zur behandlung von brustkrebs und herstellungsverfahren dafür | |
EP3725896A4 (de) | Verfahren zur unterstützung des nachweises von brustkrebs | |
IL263059A (en) | A method for treating cancer by targeting myeloid-derived suppressor cells | |
GB201717945D0 (en) | Method for treatment of cancer | |
IL274277A (en) | A method for reducing side effects of anti-CD30 drug-antibody couple therapy | |
SG11202013190YA (en) | Combination therapy with targeted tgf-b inhibition for treatment of advanced non-small cell lung cancer | |
IL273874A (en) | A method to reduce the side effects of drug-linked anti-CD30 antibody therapy | |
EP3442555A4 (de) | Verfahren zur behandlung von brustkrebs |